XORTX Therapeutics
XRTXXORTX Therapeutics Inc. (NASDAQ: XRTX) is a Canadian, clinical-stage biotechnology company. Its primary business focus is the development of novel therapeutic products to treat progressive kidney diseases. The company’s research is specifically centered on addressing conditions driven by pathogenic elevated levels of uric acid, a known contributor to renal function decline. The company’s lead product candidate is oxypurinol, a xanthine oxidase inhibitor. XORTX is investigating this therapy in a Phase 3 clinical trial, named XRX-OXY-301, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company’s clinical strategy is based on the hypothesis that lowering uric acid may slow disease progression in this patient population. XORTX is also developing XRX-008, a program targeting renal disease associated with type 2 diabetes. As a publicly traded entity, XORTX Therapeutics operates within the biotechnology and nephrology sectors. Its work is directed at conditions where high uric acid is implicated, including ADPKD and chronic kidney disease. The company’s activities encompass clinical development, regulatory strategy, and intellectual property management related to its portfolio of therapeutic candidates.
XRTX · Stock Price
Historical price data
About
XORTX Therapeutics Inc. (NASDAQ: XRTX) is a Canadian, clinical-stage biotechnology company. Its primary business focus is the development of novel therapeutic products to treat progressive kidney diseases. The company’s research is specifically centered on addressing conditions driven by pathogenic elevated levels of uric acid, a known contributor to renal function decline. The company’s lead product candidate is oxypurinol, a xanthine oxidase inhibitor. XORTX is investigating this therapy in a Phase 3 clinical trial, named XRX-OXY-301, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company’s clinical strategy is based on the hypothesis that lowering uric acid may slow disease progression in this patient population. XORTX is also developing XRX-008, a program targeting renal disease associated with type 2 diabetes. As a publicly traded entity, XORTX Therapeutics operates within the biotechnology and nephrology sectors. Its work is directed at conditions where high uric acid is implicated, including ADPKD and chronic kidney disease. The company’s activities encompass clinical development, regulatory strategy, and intellectual property management related to its portfolio of therapeutic candidates.